<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04686487</url>
  </required_header>
  <id_info>
    <org_study_id>HOCM2018044</org_study_id>
    <nct_id>NCT04686487</nct_id>
  </id_info>
  <brief_title>SterEotactic AbLative Radiotherapy in PatiEnts With HypertrophiC ObstrucTive Cardiomyopathy</brief_title>
  <acronym>SELECT</acronym>
  <official_title>Stereotactic Ablative Radiotherapy in Patients With Hypertrophic Obstructive Cardiomyopathy: First in Man Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertrophic obstructive cardiomyopathy (HOCM) is an inherited myocardial disease which leads&#xD;
      to the muscle in the wall of the heart growing and thickening to the point that it blocks&#xD;
      blood flow exiting the heart with increasing risk of sudden cardiac death, heart failure, and&#xD;
      atrial fibrillation. Surgical septal myectomy and alcohol septal ablation are two invasive&#xD;
      therapies for drug-refractory symptomatic patients with HOCM. Unfortunately, some patients&#xD;
      may be unsuitable for both the two procedures. Recently, stereotactic ablative radiotherapy,&#xD;
      usually used for the treatment of tumours, was confirmed to be feasible, safe and effective&#xD;
      in destroying abnormal tissue in heart by targeting high energy heavy ion beams at a specific&#xD;
      area of the body precisely. In this study we will determine whether radiation ablation, can&#xD;
      be used to destroy the thick heart muscle at the point of obstruction safely and effectively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of stereotactic ablative radiotherapy</measure>
    <time_frame>3 months</time_frame>
    <description>The primary safety endpoint is defined as serious adverse events (SAEs) that are possibly/probably/definitely related to study treatment, based on previously published data for expected invasive alcohol septal-ablation procedures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of MACE endpoints</measure>
    <time_frame>1, 3, 6 and 12 months</time_frame>
    <description>death, heart failure, myocardial infarction and stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of complete heart block, atrial or ventricular arrhythmias</measure>
    <time_frame>1, 3, 6 and 12 months</time_frame>
    <description>diagnosis by electrocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LVOT gradient</measure>
    <time_frame>1, 3, 6 and 12 months</time_frame>
    <description>Assessed with transthoracic echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in exercise capacity</measure>
    <time_frame>1, 3, 6 and 12 months</time_frame>
    <description>6 minute Walk Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LV wall thickness</measure>
    <time_frame>1, 3, 6 and 12 months</time_frame>
    <description>Measured on echocardiography</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Hypertrophic Obstructive Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Stereotactic Ablative Radiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stereotactic body radiation therapy delivered to the thick heart muscle at the point of obstruction</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>stereotactic ablative radiotherapy</intervention_name>
    <description>stereotactic ablative radiotherapy by targeting high energy heavy ion beams at a specific area of the body</description>
    <arm_group_label>Stereotactic Ablative Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged â‰¥ 18 years&#xD;
&#xD;
          -  Drug-refractory symptomatic patients with HOCM&#xD;
&#xD;
          -  Willing and able to give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Enrolled in another clinical study.&#xD;
&#xD;
          -  Patient unable to tolerate lying flat for one hour&#xD;
&#xD;
          -  Pregnant Or Lactating Women&#xD;
&#xD;
          -  With other contraindications for receive stereotactic ablative radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shenghua Zhou</last_name>
    <phone>86 073185292013</phone>
    <email>zhoushenghua@csu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shenghua Zhou</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Xiangya Hospital of Central South University</investigator_affiliation>
    <investigator_full_name>Shenghua Zhou</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hypertrophic Obstructive Cardiomyopathy</keyword>
  <keyword>Stereotactic Ablative Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

